Targeting C-reactive protein for the treatment of cardiovascular disease

@article{Pepys2006TargetingCP,
  title={Targeting C-reactive protein for the treatment of cardiovascular disease},
  author={Mark B. Pepys and Gideon M. Hirschfield and Glenys A. Tennent and J. Ruth Gallimore and Melvyn C. Kahan and Vittorio Bellotti and Philip N. Hawkins and Rebecca M. Myers and Martin Derrick Smith and Alessandra Polara and Alexander J. A. Cobb and Steven V. Ley and J. Andrew Aquilina and Carol V. Robinson and Isam Sharif and Gillian A. Gray and Caroline A. Sabin and Michelle C. Jenvey and Simon E Kolstoe and Darren A. Thompson and Steve P. Wood},
  journal={Nature},
  year={2006},
  volume={440},
  pages={1217-1221}
}
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein… Expand
Inhibiting C-Reactive Protein for the Treatment of Cardiovascular Disease: Promising Evidence from Rodent Models
TLDR
Evaluating the efficacy of CRP specific ASOs in rodents with experimentally induced cardiovascular damage might pave the way towards a placebo-controlled trial that could clarify the role ofCRP in cardiovascular disease. Expand
C-reactive protein and coronary disease: is there a causal link?
TLDR
Several recent findings have reduced the likelihood that CRP itself is a major causal mediator in CHD, and the strengths and limitations of the available data are summarized. Expand
Human C-Reactive Protein Enhances Vulnerability of Immature Rats to Hypoxic-Ischemic Brain Damage: A Preliminary Study
TLDR
Investigation of the hypothesis that C-reactive protein (CRP), which is not specific for infection, aggravates vulnerability of the immature brain to HI, suggests that human CRP-enhanced susceptibility to HI-induced brain damage is suggested. Expand
A novel peptide inhibitor attenuates C-reactive protein's pro-inflammatory effects in-vivo.
TLDR
It is demonstrated that the novel peptide inhibitor attenuates the proinflammatory effects of CRP in-vivo and the long-term effects of this inhibitor on vascular pathobiology will be examined. Expand
The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
  • H. Seo
  • Medicine
  • Korean circulation journal
  • 2012
TLDR
Patients with high CRP concentrations are more likely to develop stroke, myocardial infarction, and significant peripheral vascular disease; a study showed that trans-fat consumption is related to high blood levels of CRP. Expand
C-reactive protein and atherothrombosis: Cause or effect?
The complex relationship between the inflammatory response and vascular injury and repair is of major importance to the pathogenesis of cardiovascular disease. CRP is not only a strong marker forExpand
Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites
TLDR
It is demonstrated that pCRP by binding to cell-derived microvesicles undergoes a structural change without disrupting the pentameric symmetry (pCRP*), which might improve the outcome of myocardial infarction, stroke and other inflammatory conditions. Expand
The effect of C-reactive protein deposition on myocardium with ischaemia-reperfusion injury in rats.
TLDR
The results strongly suggest the active participation of the deposition of CRP on AAR in the progression of myocardial infarction following ischaemia-reperfusion injury, accompanied by complement activation and mitochondrial change. Expand
Role of C-Reactive Protein at Sites of Inflammation and Infection
TLDR
mounting evidence that CRP isoforms have distinct biological properties, with nCRP often exhibiting more anti-inflammatory activities compared to mCRP, and further studies are needed to expand on these emerging findings. Expand
Role of C-reactive protein in cerebrovascular disease: a critical review
TLDR
A critical appraisal of the strengths and deficiencies of the accumulated evidence is required, both to consider the current state of knowledge and to inform the design of future research. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats
  • R. Gill, J. Kemp, C. Sabin, M. Pepys
  • Medicine
  • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2004
TLDR
It is shown that adult rats subjected to middle cerebral artery occlusion and then treated with human CRP similarly developed significantly larger cerebral infarcts compared with control subjects receiving human serum albumin. Expand
The physiological structure of human C-reactive protein and its complex with phosphocholine.
TLDR
The structure shows how large ligands containing PC may be bound by CRP via a phosphate oxygen that projects away from the surface of the protein, inviting the design of inhibitors of CRP binding that may have therapeutic relevance to the possible role ofCRP in atherothrombotic events. Expand
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.
TLDR
It is shown that transgenic expression of human CRP had no effect on development, progression, or severity of spontaneous atherosclerosis, or on morbidity or mortality, in male apolipoprotein E (apoE)-deficient C57BL/6 mice up to 56 weeks, despite deposition of humanCRP and mouse complement component 3 in the plaques. Expand
Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability
TLDR
Pure human CRP has specific, direct effects on vascular function in vitro via increased NO production; however, further clarification of the effect, if any, of CRP on vascular reactivity in humans in vivo will require clinical studies using specific inhibitors ofCRP. Expand
Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself
TLDR
It is confirmed that this recombinant CRP preparation was proinflammatory both for mouse macrophages in vitro and for mice in vivo, but it is shown that pure natural human CRP had no such activity. Expand
Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation.
TLDR
It is reported that addition of LDL and CRP to human serum did not result in significant C3 turnover, and results indicated that CRP binds to phosphorylcholine groups that become exposed in enzymatically degraded LDL particles. Expand
Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction.
TLDR
The data suggest that acute tissue injury, such as myocardial infarction, rapidly leads to acceleration in synthesis of CRP, and that the duration of this period of acceleration is related to the extent of tissue injury. Expand
C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide
TLDR
It is concluded that CRP, per se, does not activate endothelial cells, and the effects of cCRP were mirrored by azide or LPS, but never CRP itself. Expand
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.
TLDR
Increased CRP production is a non-specific response to tissue injury and raised CRP levels in cases of chest pain with a normal CK MB indicated a pathological process other than myocardial infarction. Expand
C-reactive protein: a critical update.
TLDR
Information is provided about CRP as a protein and an acute-phase reactant, and a knowledge-based framework for interpretation and analysis of clinical observations of CRP in relation to cardiovascular and other diseases, that identifies it as a possible therapeutic target. Expand
...
1
2
3
4
5
...